ACME  ABC
  • ACME ABC
    Share

Trial Status

Open

Cancer Type

Biliary tract cancer

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

Australian Comprehensive Molecular Evaluation of Advanced Biliary Cancer (ACME ABC) Trial

Purpose of the Study

Biliary cancer (BC) remains a rare but important cause of cancer related mortality. Surgical resection is the only potentially curative treatment; however, the majority of patients present with advanced biliary cancer (ABC) are not surgical candidates. Instead, these patients are offered palliative chemotherapy. The median survival of patients with ABC is between 1-2 years.

The ACME ABC study will review the feasibility and potential benefit of instituting routine comprehensive molecular profiling of patients with ABC using either fresh, frozen or archival tissue obtained at the time of routine diagnostic tests.

Contact email

agitg@gicancer.org.au

Detailed information available

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.

Study Chairs

Dr Daniel Croagh
Dr Owen McKay

funding

2021 AGITG-Pancare Cholangiocarcinoma Idea Generation Workshop Grant

Participating Centres

South Australia
Royal Adelaide Hospital
Victoria
Monash Medical Centre

Trial Status

Open

Cancer Type

Biliary tract cancer

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.

Participating Centres

South Australia
Royal Adelaide Hospital
Victoria
Monash Medical Centre